Financials in USD. Standardized financial statements.
A compact view of how Inovio Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $65,343 | $217,756 | $832,010 | $10.26M | $1.77M | $7.41M | $4.11M | $30.48M | $42.22M | $35.37M |
| Revenue Growth? | -70.0% | -73.8% | -91.9% | +478.2% | -76.1% | +80.2% | -86.5% | -27.8% | +19.4% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $65,343 | $217,756 | $832,010 | $10.26M | $1.77M | $7.41M | $4.11M | $30.48M | $42.22M | $35.37M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% |
| Operating Expenses? | $86.89M | $112.62M | $144.77M | $277.84M | $302.99M | $131.49M | $115.22M | $124.57M | $126.86M | $112.60M |
| Operating Income? | -$86.82M | -$112.40M | -$143.94M | -$267.57M | -$301.22M | -$124.08M | -$111.11M | -$94.09M | -$83.64M | -$76.24M |
| EBITDA? | -$81.96M | -$103.95M | -$130.39M | -$270.90M | -$296.56M | -$149.56M | -$107.34M | -$89.80M | -$84.74M | -$74.15M |
| Income Before Tax | -$84.95M | -$107.25M | -$135.12M | -$279.82M | -$303.66M | -$167.47M | -$120.81M | -$94.80M | -$88.21M | -$73.74M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | -$257,335 | $2.17M | $0 | $0 |
| Net Income? | -$84.95M | -$107.25M | -$135.12M | -$279.82M | -$303.66M | -$166.41M | -$119.36M | -$96.97M | -$88.21M | -$73.74M |
| EPS? | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-1.42 | $-1.07 | $-0.97 | $-1.05 | $-1.08 | $-1.01 |
| Diluted EPS? | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-1.42 | $-1.07 | $-0.97 | $-1.05 | $-1.08 | $-1.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality